SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rocketman who wrote (353)5/16/1997 11:36:00 PM
From: NeuroInvestment   of 998
 
Actually, while you are correct regarding Rescriptor, your conclusion regarding terminal illness priorities is not correct. Late in 1996 the Advisory Committee reviewing sibutramine for obesity (from Knoll) voted against it, the FDA overruled them and declared it approvable about two months later . Though obesity is not cosmetic, it is not terminal in the usual sense. The FDA will repeat the move for Myotrophin, because this is the hottest political football that they are going to be juggling during a summer of congressional hearings on User Fee and budget legislation. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News